



Pressure BioSciences, Inc.

Ticker: PBIO (OTCQB)

Corporate Profile

as of May 31, 2016

Pressure BioSciences, Inc. (OTCQB: PBIO) is a medical research products and technology company. PBI, based in South Easton, Massachusetts, serves academic and government laboratories, as well as biotechnology, pharmaceutical, and other life sciences companies.

PBI recently signed an exclusive, two-year co-marketing agreement with a large strategic partner named SCIEX, which offers tremendous potential for revenue growth. SCIEX is a global leader in life sciences analytical technologies and a wholly-owned subsidiary of the Danaher Corporation (NYSE: DHR).

The PBI technology platform is based on constant (i.e., static) and alternating (i.e., Pressure Cycling Technology, or PCT) hydrostatic pressure; if used properly, pressure can help control the actions of molecules in biological samples, which can then have significant positive effects on scientific research studies.

The market for PBI consists of an estimated 500,000 scientists in over 80,000 research laboratories worldwide. PBI's development and sales efforts are in the biomarker discovery, drug discovery/design, and forensics areas.

In April 2016, PBI completed an intensive, one-year project that called for the design and build of the initial working model ("breadboard") of the its new and improved Barocycler 2320EXTREME instrument.

PBI has recently come to an arrangement with a local ISO-certified contract manufacturer, and has given the manufacturer an initial order for 30 Barocycler 2320EXT units. The manufacture of the initial four, commercial-grade units was completed on May 27, 2016.

PBI is poised for rapid growth during 2016 with the introduction of its new and enhanced products, buoyed by its expanded marketing and sales initiatives. Solid product sales growth of 26% during Q1 2016 along with a significantly improved balance sheet has positioned PBI for this anticipated rapid growth.



Income Statement	FY 2014	FY 2015	3/31/16	Balance Sheet	FY 2014	FY 2015	3/31/16	Cash Flow Statement	FY 2014	FY 2015	3/31/16
Revenue	1,374,744	1,797,691	510,478	Cash & cash equivalents	473,948	116,783	93,387	Operating Cash Flow	(3,210,578)	(3,819,746)	(1,233,458)
Gross Profit	697,712	800,937	288,779	Total Assets	1,744,132	1,804,388	1,967,508	Investing Cash Flow	(7,139)	(9,412)	-
Operating Loss	(3,338,350)	(3,565,182)	(1,045,945)	Total Liabilities	3,803,863	9,782,036	15,828,583	Financing Cash Flow	3,660,248	3,471,993	1,210,062
Net Loss	(4,612,540)	(7,415,298)	(5,950,391)	Total Shareholder's Equity	(2,059,731)	(7,977,648)	(13,861,075)	Cash at end of period	473,948	116,783	93,387



Sector: Healthcare
Industry: Medical Devices & Technology

Website: www.pressurebiosciences.com

Key Statistics

Table with 2 columns: Metric and Value. Includes Price 5/31/2016 (0.48), 52 Week High (0.58), 52 Week Low (0.20), Avg. Vol (30day) (78,967), Beta (0.29), Market Cap (Interday) (13.27M), Insider Ownership (%) (10.3%), Shares Outstanding (M) (23.21), Float (M) (19.93), EPS(ttm) (-0.52).

Source: Cap IQ/Google Finance

Recent 2016 Highlights

- May 18, 2016 PBI announced 26% product revenue growth for the first quarter, including strong instrument and consumable sales.
April 12, 2016, PBI was added to the high-performing Richmond Club Index.
March 31, 2016, PBI closed an additional \$769K in PIPE financing.
March 14, 2016, PBI announced that it would participate in the SCIEX Workshop on New Innovations Towards Industrialized Proteomics.
October 2015, PBI announced a collaboration agreement with Florida International University.

Corporate Contact Information

Pressure BioSciences Inc.
Richard T. Schumacher, CEO
14 Norfolk Ave. South Easton MA, 02375
Phone: 508-230-1828
www.pressurebiosciences.com